Alcidion Group Ltd (ASX: ALC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Alcidion Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Alcidion Group Ltd (ASX: ALC)
Latest News
Technology Shares
This ASX technology company's shares are surging more than 20% on a new contract win
Earnings Results
Up 94% in a year, why is this ASX healthcare stock rocketing again today?
Healthcare Shares
Guess which ASX healthcare stock is rocketing 25% on big UK news
Healthcare Shares
2 ASX healthcare shares outperforming on big news
Healthcare Shares
Guess which ASX healthcare stock just rocketed 46% on major news!
Healthcare Shares
Why is the Alcidion share price crashing 27% to a 52-week low?
Broker Notes
400% organic growth in 3 years: The ASX small-cap Cyan is pumped about
Opinions
An unloved ASX stock I'm considering buying with $5,000 in August
Earnings Results
Alcidion share price charges 9% ahead on record quarter
Small Cap Shares
'Upside surprise': 2 small-cap ASX shares ready to break out
Broker Notes
Leading brokers name 3 ASX shares to buy today
Growth Shares
ASX shares: Invest in these 2 stocks for a legit chance at $1 million
Frequently Asked Questions
-
No, Alcidion does not pay dividends at this time.
-
Alcidion listed on the ASX on 24 June 2011.
ALC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Alcidion Group Ltd
Alcidion Group Ltd (ASX: ALC) is a provider of intelligent informatics software for the healthcare sector.
The company builds, sells, delivers, runs, and supports solutions for healthcare providers. These include clinical, analytical, managerial, and administrative systems.
Its products include its Miya suite, a Fast Healthcare Interoperability Resources (FHIR) system that allows comprehensive healthcare data to be exchanged between different computer systems. Other products include Smartpage and Patientrack software.
Alcidion derives the majority of its revenue from its Australia/New Zealand segment and also has a presence in the United Kingdom.
ALC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 14 Jan 2026 | $0.14 | $0.02 | 16.67% | 14,378,555 | $0.13 | $0.14 | $0.12 |
| 13 Jan 2026 | $0.12 | $0.00 | 0.00% | 5,846,019 | $0.12 | $0.13 | $0.11 |
| 12 Jan 2026 | $0.12 | $0.00 | 0.00% | 2,400,747 | $0.12 | $0.12 | $0.11 |
| 09 Jan 2026 | $0.12 | $0.00 | 0.00% | 1,742,881 | $0.12 | $0.12 | $0.11 |
| 08 Jan 2026 | $0.12 | $0.02 | 20.20% | 14,374,252 | $0.12 | $0.12 | $0.11 |
| 07 Jan 2026 | $0.10 | $0.00 | 0.00% | 515,462 | $0.10 | $0.10 | $0.10 |
| 06 Jan 2026 | $0.10 | $0.00 | 0.00% | 4,624,022 | $0.10 | $0.11 | $0.10 |
| 05 Jan 2026 | $0.10 | $0.00 | 0.00% | 240,443 | $0.11 | $0.11 | $0.10 |
| 02 Jan 2026 | $0.10 | $0.00 | 0.00% | 316,824 | $0.11 | $0.11 | $0.10 |
| 31 Dec 2025 | $0.11 | $0.00 | 0.00% | 32,720 | $0.11 | $0.11 | $0.10 |
| 30 Dec 2025 | $0.10 | $0.00 | 0.00% | 92,134 | $0.11 | $0.11 | $0.10 |
| 29 Dec 2025 | $0.10 | $0.00 | 0.00% | 184,663 | $0.11 | $0.11 | $0.10 |
| 24 Dec 2025 | $0.11 | $0.01 | 10.20% | 31,751 | $0.11 | $0.11 | $0.10 |
| 23 Dec 2025 | $0.10 | $0.00 | 0.00% | 554,525 | $0.11 | $0.11 | $0.10 |
| 22 Dec 2025 | $0.10 | $0.00 | 0.00% | 800,109 | $0.10 | $0.11 | $0.10 |
| 19 Dec 2025 | $0.10 | $0.00 | 0.00% | 124,993 | $0.10 | $0.11 | $0.10 |
| 18 Dec 2025 | $0.10 | $0.00 | 0.00% | 17,635 | $0.11 | $0.11 | $0.10 |
| 17 Dec 2025 | $0.10 | $0.00 | 0.00% | 1,153,595 | $0.11 | $0.11 | $0.10 |
| 16 Dec 2025 | $0.11 | $0.00 | 0.00% | 99,881 | $0.11 | $0.11 | $0.11 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 04 Mar 2025 | Katrina (Kate) Doyle (Quirke) | Sell | 5,000,000 | $425,000 |
Off-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Rebecca Jayne Wilson | Non-Executive DirectorNon-Executive Chairman | Jul 2017 |
Ms Wilson is an experienced company director with private, ASX listed and not-for-profit organisations. In her previous executive career, she held global leadership roles in marketing communication, investor relations, and corporate affairs. She has experience in ESG stakeholder communication, issues, crisis and risk management, transactions, and investor relations. She has worked with multinational and growth companies in technology, healthcare, retail, and professional services sectors. Rebecca is experienced in leading companies during important commercial activation phases working with CEOs as both an advisor and non-executive director to develop and execute effective business strategy that supports accelerated and sustained growth. She's a Non-Executive Director of NFP, The Tomisich Foundation and Veski.
|
| Mr William (Bill) Smart | Non-Executive Director | Oct 2024 |
Mr Smart is a global digital health leader with over 30 years of experience leading transformational change in organisations. Will has a track record of driving politically sensitive and operationally critical initiatives, enhancing organisational performance. Based in the United Kingdom, Will is currently Digital Non-Executive Director, Great Western Hospitals NHS Foundation Trust and was previously the CIO for Health and Social Care for England. In that role, Will provided advice to the Secretary of State for Health and Social Care and developed and delivered national strategies on information, technology and informatics. He has held executive roles in several NHS Trusts including as Group Chief Information Officer, Royal Free London NHS Foundation Trust. Until recently, Will served as the Global Director of External Relations, Dedalus Group where he had responsibilities across the UK and Europe and led the launch of their European built Electronic Patient Record (EPR) solution into Ireland and the UK. He is member of the Risk Committee.
|
| Ms Katrina (Kate) Elizabeth Doyle (Quirke) | Chief Executive OfficerExecutive DirectorManaging Director | Jul 2018 |
Ms Doyle, since July 2018, has been the Group Managing Director and Chief Executive Officer of the Alcidion Group, a company dedicated to providing smart technology to the health sector. Kate leads the business globally with a goal of developing mutually beneficial relationships with customers, partners and investors. Kate has 25 plus years of digital health sector experience and has been involved in procurements and implementations of healthcare information technology across Australia, New Zealand, the United Kingdom and South-East Asia. Her background includes management roles at healthcare software firms where she has driven strategic product direction, global sales and operations. She believes technology can enable the transformation of healthcare delivery. Kate is currently a Non-Executive Director of ANDHealth, Australia's provider of accelerator, incubator and commercialisation programs for digital health technology companies.
|
| Mr Daniel Sharp | Non-Executive Director | Sep 2021 |
Mr Sharp originally commencing his career as a lawyer and has over 25 years senior executive experience in investment banking and corporate finance. From 2012-2020, Danny was an Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to his executive role at Canaccord, Danny headed the corporate finance division at two of Australia's independent Investment Banking/Stockbroking firms. Danny has managed the IPOs, capital raisings and corporate advisory activities for ASX listed companies in the healthcare, technologies and general industrials sectors. He is connected to strong networks of institutional, family office and investors both in Australia and overseas. Danny is currently Non-Executive Chair of VetScripts Pty Ltd and a member of the Investment Committee for the Baker Heart and Diabetes Institute Foundation. He is chair of the Risk Committee.
|
| Professor Andrew Way | Non-Executive Director | Apr 2025 |
Mr Way commenced his career as a nurse in the UK National Health Service (NHS) and after a range of clinical positions, moved first into nursing leadership and then in the late 1980's into general management. Andrew has held several senior executive roles in research-focussed hospitals in both the UK NHS and Australia. He has been a Chief Executive for nearly 25 years, most recently as the CEO of Alfred Health in Melbourne, Victoria, finishing in 2024. Andrew has led several hospitals through clinical and non-clinical digital transformations. Andrew is currently Board Chair of HealthShare Victoria and a Director of Australian College of Health Service Management (ACHSM). He was Interim CEO at the Royal Australian New Zealand College of Psychiatrists between December 2024 and July 2025. He continues to hold a range of other health related advisory roles. He is member of the Risk Committee.
|
| Mr Michael Sapountzis | Company Secretary | Mar 2019 |
-
|
| Matthew Gepp | Chief Financial Officer |
-
|
|
| Michael Sapountzis | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| J P Morgan Nominees Australia Pty Limited | 209,178,732 | 15.58% |
| Mr Malcolm Pradhan | 116,416,160 | 8.67% |
| Mr Raymond Howard Blight | 68,664,657 | 5.11% |
| Bond Street Custodians Limited <Salter D79836 A/C> | 50,000,000 | 3.72% |
| Mr Paul John Van Dyk | 34,608,937 | 2.58% |
| Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 28,824,376 | 2.15% |
| Rewmicman Pty Ltd <Smallman Family A/C> | 27,266,938 | 2.03% |
| Mrs Katrina Elizabeth Doyle | 22,793,199 | 1.70% |
| MNMD Pty Ltd <Quirke Super Fund A/C> | 20,668,086 | 1.54% |
| Caledonia Nominees Pty Ltd <Caledonia A/C> | 19,976,377 | 1.49% |
| Citicorp Nominees Pty Limited | 15,222,342 | 1.13% |
| Mr Dean Anthony Mackenzie | 14,557,240 | 1.08% |
| Sandhurst Trustees Ltd <Cyan C3G Fund A/C> | 11,469,114 | 0.85% |
| Ubs Nominees Pty Ltd | 9,840,656 | 0.73% |
| Netwealth Investments Limited <Wrap Services A/C> | 8,050,478 | 0.60% |
| Bond Street Custodians Limited <Rsalte D62375 A/C> | 8,050,000 | 0.60% |
| Rangiora London Pty Limited <Rangiora London A/C> | 7,800,000 | 0.58% |
| Emerald Shares Pty Limited <Emerald Unit A/C> | 7,100,000 | 0.53% |
| Mr Vivek Ramakrishnan and Miss Nisha Srinivasan | 7,021,913 | 0.52% |
| Mast Financial Pty Ltd <A To Z Investment A/C> | 6,425,000 | 0.48% |